Anti-Human HLA-DQ (MHC Class II) – Purified in vivo GOLD™ Functional Grade

Anti-Human HLA-DQ (MHC Class II) – Purified in vivo GOLD™ Functional Grade

Product No.: H262

[product_table name="All Top" skus="H262"]

- -
- -
Clone
1a3
Target
HLA-DQ
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
HLA-DQ Monomorphic
Isotype
Mouse IgG2a
Applications
ELISA
,
FC
,
in vivo
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Unknown
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this HLA-DQ (Clone 1a3) antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this HLA-DQ (Clone 1a3) antibody for use in western blotting is 1-10 μg/ml.
ELISA
Additional Applications Reported In Literature ?
IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 1a3 recognizes a monomorphic epitope on human HLA-DQ1. It does not cross-react with HLA-DR or HLA-DP.
Background
HLA-DQ antibody, clone 1a3, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DQ isotype (HLA-DQ). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation2. HLA-DQ consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain3 encoded by the HLA-DQA1 and HLA-DQB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens4. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling5. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation6 and can transduce signals into T cells, enhancing T cell proliferation and activity7. Specific alleles of HLA-DQ are associated with autoimmune diseases, including celiac disease8 and type 1 diabetes9, and graft-versus-host disease10.
Antigen Distribution
HLA-DQ is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.
Ligand/Receptor
CD3/TCR, CD4
PubMed
NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

References & Citations

1. Shookster L, et al. (1987) Hum Immunol. 20(1):59-70
2. Holling TM, Schooten E, van Den Elsen PJ. (2004) Hum Immunol. 65(4):282-90
3. Mitaksov V, Fremont DH. (2006) J Biol Chem. 281(15):10618-25
4. Wieczorek M, et al. (2017) Front Immunol. 8:292
5. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
6. Barnaba V, et al (1994) Eur J Immunol. 24(1):71-5
7. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60
8. Castaño L, et al. (2004) J Pediatr Gastroenterol Nutr. 39:80–84
9. Cucca F, et al. (1993) Hum Immunol. 37:85 –94
10. Petersdorf EW, (1996) Proc Natl Acad Sci USA. 93(26):15358-63
11. Matsuoka T, et al. (2001) J Immunol. 166(4): 2202–2208
Indirect Elisa Protocol
Flow Cytometry
in vivo Protocol
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.